It targets multiple signaling pathways implicated in tumor proliferation, angiogenesis, and the tumor microenvironment, including vascular endothelial growth factor receptors (VEGFR1-3), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and oncogenic kinases such as KIT and RET. This evidence concerns the gene FLT1 and neoplasm.